Application of scanning acoustic microscopy for evaluation of MMP activation in multiple cancer cell lines with a smart probe.

Background/aim: Matrix metalloproteinases (MMPs) play an important role in the evaluation of many cancer types; however, the detection usually presents a challenge. Further assays for a better understanding of the fundamental roles of MMPs in pathophysiology are still needed. We aimed to use an activatable probe in scanning acoustic microscopy (SAM) to evaluate acoustically if the probe can aid the visualization of the effects of in vitro MMP activity. Materials and methods: We applied scanning acoustic impedance microscopy to obtain acoustic impedance maps of the cell line models of HT1080, THP-1, and SK-MEL-28 with and without MMPSense 680 probe incubation. We visually validated our results using confocal laser scanning microscopy imaging. We further analyzed the effects of MMPSense 680 probe on cell viabilities to eliminate any artifacts. Results: This is the first study presenting the applicability of SAM in the acoustical evaluation of MMPSense 680 probe cleavage in a cellular medium through acoustic impedance measurements. We proposed that SAM measurement with the activatable probe can be used as an effective tool for studying the acoustical variations of MMP activities in cell lines. As a result, we detected MMPSense 680 probe cleavage in HT1080 human fibrosarcoma cell line. Conclusion: We showed that SAM with the smart probe can detect proteolytic activity using MMPSense 680 in in vitro HT1080 cell line by acoustic impedance measurements. SAM could be proposed as an alternative tool leading a novel way for a better understanding of the roles of MMPs in cancer progression before clinical settings.

Previously unreported abnormalities in Wolfram Syndrome Type 2.

Wolfram syndrome (WFS) is a rare autosomal recessive disease with non-autoimmune childhood onset insulin dependent diabetes and optic atrophy. WFS type 2 (WFS2) differs from WFS type 1 (WFS1) with upper intestinal ulcers, bleeding tendency and the lack ofdiabetes insipidus. Li-fespan is short due to related comorbidities. Only a few familieshave been reported with this syndrome with the CISD2 mutation. Here we report two siblings with a clinical diagnosis of WFS2, previously misdiagnosed with type 1 diabetes mellitus and diabetic retinopathy-related blindness. We report possible additional clinical and laboratory findings that have not been pre-viously reported, such as asymptomatic hypoparathyroidism, osteomalacia, growth hormone (GH) deficiency and hepatomegaly. Even though not a requirement for the diagnosis of WFS2 currently, our case series confirm hypogonadotropic hypogonadism to be also a feature of this syndrome, as reported before.

Etoposide resistance in MCF-7 breast cancer cell line is marked by multiple mechanisms.

PURPOSE: Acquired or intrinsic drug resistance is one of the major handicaps in the success of chemotherapy. Etoposide is a topoisomerase II poison widely used in chemotherapy. Similar to other topoisomerase inhibitors and DNA damaging agents, resistance to etoposide may arise as a result of alterations in target expression and activity, increased drug efflux and alterations in DNA damage response mechanisms. Here, we tested the involvement of such mechanisms in etoposide-resistant MCF-7 breast cancer cells. METHODS: Relative etoposide resistance was determined by XTT cell proliferation assay. For gene expression analysis, total RNA was extracted from each cell line and gene expression was quantified by real-time PCR following reverse transcription. Topoisomerase II activities of each cell line were compared by using in vitro topoisomerase II activity assay. RESULTS: Etoposide-resistant sublines MCF-7/1E and MCF-7/4E are 2.6- and 4.6-fold more resistant to etoposide compared to parental cell line MCF-7/S. TOP2A, the gene encoding the topoisomerase II alpha, is significantly downregulated in drug resistant sublines while topoisomerase II activity seemed similar among cell lines. MRP1, which encodes an etoposide efflux pump, is significantly upregulated in etoposide-resistant sublines. Two DNA damage response proteins TOPBP1 and EDD were found to be downregulated in etoposide-resistant sublines. CONCLUSIONS: This study sheds light into the etoposide resistance in breast cancer by investigating previously proposed and novel factors that may have a role in development or progression of etoposide resistance which can be considered as diagnostic markers and therapy targets.